Journal of Current Oncology最新文献

{"title":"The Prognostic Role of VEGFR-2 Gene Amplification in Relation to Serum AFP Levels Among Liver-Transplanted Patients with Hepatocellular Carcinoma","authors":"Ulkuhan I Koksal, S. Saglam, M. Dayangaç, G. Dogusoy, M. Akyildiz, Murat Buyukdogan, Egzona Qipa","doi":"10.1177/25898892221145210","DOIUrl":"https://doi.org/10.1177/25898892221145210","url":null,"abstract":"Background Hepatocellular carcinoma (HCC) is the most common primary liver neoplasia. Vascular endothelial factor receptor 2 (VEGFR-2) plays an important role in angiogenesis and it has been associated with poor survival in certain other tumor types. Although a recent study also suggested an association between VEGFR-2 expression and HCC, the relationship between VEGFR-2 amplification and HCC is still obscure. Aim To evaluate prognostic role of vascular endothelial growth factor receptor 2 (VEGFR-2) amplification in relation to serum alpha-fetoprotein (AFP) levels and tumor clinicopathological parameters among liver-transplanted patients with HCC. Study design Cohort study Methods A total of 54 formalin-fixed paraffin-embedded and frozen HCC samples from patients who underwent liver transplantation between 2009 and 2015 were analyzed. VEGFR-2 amplification was determined via fluorescence in situ hybridization (FISH) method in tissue samples obtained during liver transplantation and analyzed with respect to serum AFP levels, tumor clinicopathological parameters, and oncological outcomes including recurrence free survival (RFS) and overall survival (OS). Results Amplified VEGFR-2 gene was prominent in 27 (50.0%) patients, while AFP levels were ≥100 ng/mL in 14 (25.9%) patients. Presence of amplified VEGFR-2 gene was associated with significantly shorter RFS time (mean 72.8 vs 101.3 months for positive and negative patients respectively, P = .015), whereas had no significant impact on OS time (median 79.2 vs 93.1 months, respectively, P = .206). Presence versus absence of amplified VEGFR-2 gene was associated with significantly higher levels of AFP (mean±SD 266.6±405.8 vs 40.6±94.6 ng/mL, P = .016) and higher recurrence rate (81.8 vs 18.2%, P = .018), and significantly predicted the AFP levels ≥100 ng/ml (OR, 10.2, 95%CI 1.8-56.9, P = .008). Lymphatic invasion and vascular invasion emerged as independent predictors of poor OS (HR, 12.4 [95% CI, 2.7-57.3], P = .01) and RFS (HR, 8.3 [95% CI, 2.3-29.8], P = .01). Conclusion In conclusion, our findings revealed the presence of amplified VEGFR-2 gene and its association with serum AFP elevation for the first time in HCC. VEGFR-2 amplification was associated with significantly shorter RFS and it emerged as a significant predictor of elevated AFP. Accordingly, our findings seem to indicate the role of AFP elevation in VEGFR-2-mediated tumorigenesis as well as the likelihood of amplified VEGFR-2 gene and high AFP levels to determine the risk status and efficacy of VEGFR-2-inhibitors in HCC liver transplanted patients.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"22 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124033626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Confounding Case of a Skin Biopsy","authors":"A. Mehta, Arupparna Sengupta, S. Pasricha, Ankur Kumar, D. Bansal","doi":"10.1177/25898892231161677","DOIUrl":"https://doi.org/10.1177/25898892231161677","url":null,"abstract":"An 88-year-old gentleman with no significant past and family history, presented with an erythematous indurated plaque-like lesion on the right leg since 3 to 4 months along with few lesions on the abdomen and chest. He had no itching sensation in the region. On examination, indurated erythematous plaques were noted. There was no ulceration of the skin. All laboratory investigations done were within normal limits. He was treated with topical steroids but it yielded no response. Subsequently, he underwent a skin biopsy from the lesional area. Grossly, skin biopsy measured 0.5 x 0.5 x 0.2 cm. On microscopic examination, skin biopsy showed thinned out atrophic epidermis with a well-defined Grenz zone in the papillary dermis (Figure 1A). There was pandermal infiltrate of diffuse sheets of neoplastic round cells intermediate in size (Figure 1B) along with dense dermal sclerosis (Figure 1D). The cells had pleomorphic convoluted nuclei with coarse chromatin and inconspicuous nucleoli (Figure 1C). Mitosis was brisk (inset). The follicular units are also surrounded and focally infiltrated by the neoplastic cells. Epidermotropism was absent.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116441726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Malignant Peripheral Nerve Sheath Tumor of Tongue: A Rare Tumor of Oral Cavity","authors":"A. Yadav, J. Goyal, Dinesh Yadav, N. Sethi, Maneesh Vijayvargiya","doi":"10.1177/25898892221145214","DOIUrl":"https://doi.org/10.1177/25898892221145214","url":null,"abstract":"Malignant peripheral nerve sheath tumor (MPNST) is a rare tumor of oral cavity. Tongue is an extremely rare site for MPNST. We present a rare case of MPNST of tongue in a 34-year-old male. Presentation remains same as carcinoma of tongue but histopathology and immunohistochemistry help to establish the diagnosis. Biopsy of lesion was suggestive of malignant spindle cell neoplasm. On immunohistochemical examination, tumor cells were immunopositive for vimentin and S100 and SMA. Patient underwent surgery followed by adjuvant radiotherapy in order to reduce the risk of recurrence.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125373263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Step-by-Step Stereotactic Radiotherapy Planning of Brain Metastasis: A Guide to Radiation Oncologists—the ROSE Case (Radiation Oncology from Simulation to Execution)","authors":"K. Patro, A. Avinash, A. Pradhan, R. R. Boya, Chitta Kundu, P. Bhattacharyya, V. Pilaka, Mrutyunjayarao Muvvala, A. Prabu, AyyalasomayajulaAnil Kumar, Srinu Aketi, P. Prasad, Venkata Naga Priyasha, V. Avidi, Mohanapriya Atchaiyalingam, Keerthiga Karthikeyan","doi":"10.1177/25898892221145226","DOIUrl":"https://doi.org/10.1177/25898892221145226","url":null,"abstract":"Brain metastasis is seen in 10% to 20% of all adult cancer patients. One of the main modalities of treatment is stereotactic radiosurgery (SRS). Here, we describe the step by step procedure for stereotactic planning of brain metastasis by using a clinical scenario. The management of brain metastasis starts with the clinical evaluation of the patient followed by imaging and SRS treatment in the present case. The paper highlights the sequential process of radiation planning for SRS—starting from simulation, planning, evaluation of plan, and treatment.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"9 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124278888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer of right breast with single-liver metastasis-simultaneous treatment of chest wall with radiotherapy for carcinoma breast and SBRT for liver lesion: Procedural details of the complex procedure","authors":"K. Patro, Venkata Damodara, Rakesh Boyya, Chitaranjan Kundu, P. Bhattacharyya, V. Pilaka, S. Padhi, Mrutyunjayarao Muvvala, P. Reddy, V. Avidi, Mohanapriya Atchaiyalingam, Keerthiga Karthikeyan, A. Prabu, Aketi Srinu, P. Prasad, A. Kumar","doi":"10.4103/jco.jco_33_21","DOIUrl":"https://doi.org/10.4103/jco.jco_33_21","url":null,"abstract":"Breast cancer with oligometastasis is not uncommon. Greater therapeutic advantage has been reported in various literatures with evolution of treatment technique. Here we report a case of ductal carcinoma right breast with a single metastasis to liver. This patient was treated with radical intent with chemotherapy, surgery, and then followed by radiotherapy to right chest wall along with stereotactic body radiotherapy for liver metastasis. Each treatment per se is not complicated. When radiation delivered to both chest wall and liver, the cumulative dose to liver is the main concern. Here we present the procedural details of this complex procedure.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"94 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128585395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emergence of SBRT in borderline resectable pancreatic cancer: Is it the way forward?","authors":"K. Talapatra, S. Karmakar, A. Gupte, A. Srivastava","doi":"10.4103/jco.jco_22_21","DOIUrl":"https://doi.org/10.4103/jco.jco_22_21","url":null,"abstract":"Pancreatic cancers are aggressive cancers with poor survival outcomes and few effective treatment modalities. The previously used protracted chemo-radiotherapy (CTRT) regimens have not had encouraging results. Stereotactic body radiotherapy (SBRT) has shown encouraging results in the treatment paradigm of borderline resectable pancreatic cancers. Though body of level I evidence is weak currently, studies have shown better resectability with negative margins with neoadjuvant SBRT. Precise contouring, good image guidance, strict quality assurance, and multi-disciplinary spatial co-operation are crucial for its success. High biologically effective dose, smaller margins, short duration of treatment, and strategic sequencing are the key to better outcomes.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"2 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130993213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumors beneath one umbrella: A story of a young man","authors":"A. Mehta, D. Karki, G. Durga, D. Bansal, V. Yadav, S. Pasricha, M. Kamboj","doi":"10.4103/jco.jco_43_21","DOIUrl":"https://doi.org/10.4103/jco.jco_43_21","url":null,"abstract":"","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"780 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134550815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adjuvant chemotherapy for stage II colon cancer: Whom to treat?","authors":"D. Pruthi, Manish Pandey, P. Nagpal","doi":"10.4103/jco.jco_20_21","DOIUrl":"https://doi.org/10.4103/jco.jco_20_21","url":null,"abstract":"The treatment of choice in stage II colon cancer is surgery, which alone has shown a high cure rate (about 80%). The role of adjuvant chemotherapy is still a matter of debate. This clinical issue leads to the need for identifying patients who may benefit from postoperative chemotherapy based on their risk of recurrence. Patients with stage II colon cancer need to be stratified according to risk factors, which can be either clinical or pathological. In this review article, we analyzed various risk factors individually and try to quantify the relative contribution of each factor. We also analyzed various chemotherapy regimens and their duration as well.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"4 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130584700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hippo pathway in cancer: Examining its potential","authors":"Mohammad Z Najm, Sadaf, V. Shingatgeri, Harsh Saha, Hiya Bhattacharya, Archita Rath, Vibhuti Verma, Apurva Gupta, Abdulaziz A. Aloliqi, Poonam Kashyap, F. Parveen","doi":"10.4103/jco.jco_9_21","DOIUrl":"https://doi.org/10.4103/jco.jco_9_21","url":null,"abstract":"The Hippo pathway was first discovered and linked to human cancers in the year 2002. It plays a crucial role in the majority of cancers, making it a censorious field for future investigation. Cancer is one of the major health issues, and there is no current cure accessible to efficiently medicate or treat the disease. The disease follows a process of oncogenesis, leading to the transformation of healthy cells (controlled and regulated growth) into cancer cells (uncontrolled and dysregulated growth). Previous studies reveal that the role of the Hippo pathway remains the center in the modulation of developmental biology. The mutated and altered gene expression of LATS1/2 (Large Tumor Suppressor kinase), MST1/2 (Member of Sterile-20 proteins kinase), and YAPs (Yes Associated Proteins), which are the chief factors of the Hippo pathway, basically promotes the invasion and migration of cancer cells. Therefore, targeting the hippo pathway genes is of utmost importance when considering new treatment strategies such as precision or personalized medicine. In this review, we aim at describing how microRNAs, hippo-signaling pathways regulate and maintain the whole hippo signaling.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":" 20","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"120830004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Step by step stereotactic planning of meningioma: A guide to radiation oncologists—the ROSE case [radiation oncology from simulation to execution]","authors":"K. Patro, A. Avinash, A. Pradhan, Suresh Tatineni, Chitta Kundu, P. Bhattacharyya, V. Pilaka, M. Rao, A. Prabu, A. Kumar, Srinu Aketi, P. Prasad, Venkata Damodara, V. Avidi, Mohanapriya Atchaiyalingam, Keerthiga Karthikeyan, Voonna Muralikrishna","doi":"10.4103/jco.jco_36_21","DOIUrl":"https://doi.org/10.4103/jco.jco_36_21","url":null,"abstract":"Background: Intracranial meningiomas account for 33% of all primary tumors of the brain. One of the main modalities of the treatment is stereotactic radiosurgery (SRS). Here, we describe the procedural steps for radiation planning of stereotactic radiotherapy (SRT) of meningioma. Methods: The step-by-step procedure for stereotactic planning of meningioma has been described using a clinical scenario of meningioma. Results: The stereotactic radiation planning of meningioma starts with the basic history and relevant clinical evaluation of various signs and symptoms of the patient followed by imaging and grading of meningioma. Magnetic resonance imaging (MRI) of the brain is the imaging modality of choice. Evaluation of surgical notes and postoperative histopathology confirmation of diagnosis should also be done. Radiation is indicated in postoperative residual or recurrent disease and in unresectable settings. The radiation planning of meningioma starts with computed tomography (CT) simulation and MRI of the brain that should be performed in prescribed format to achieve uniformity in radiation planning. After CT and MRI fusion, contouring of target, organs at risk (OAR), and radiation planning should be performed. The plan evaluation includes target and OAR coverage index, conformity, homogeneity and gradient index, and beam arrangement. After radiation plan evaluation, the treatment is delivered after quality assurance and dry run. Conclusion: The article highlights the sequential process of radiation planning for SRT of meningioma—starting from simulation to planning, evaluation of plan, and treatment.","PeriodicalId":315168,"journal":{"name":"Journal of Current Oncology","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121444819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}